Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:VSNT News 5 January 2026 - 11 January 2026

Comcast’s Versant spinoff is done — what’s inside VSNT and why CMCSA shares slid

Comcast’s Versant spinoff is done — what’s inside VSNT and why CMCSA shares slid

NEW YORK, January 5, 2026, 09:30 EST Comcast (CMCSA) said on Monday it completed the spinoff of its NBCUniversal cable networks into Versant Media Group, distributing shares of the new company to existing investors. Versant (VSNT) began trading on Nasdaq and was down 3.5% in premarket trading. Comcast has said the assets generate about $7 billion in annual revenue. Reuters The separation lands as U.S. pay-TV bundles keep shrinking and streaming pulls viewers toward on-demand platforms. For Comcast, it peels off slower-growing cable channels that once anchored its media unit. Investors now get two stocks to price: Comcast’s remaining businesses
5 January 2026
··

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop